1-TFMB KG

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-TFMB KG
• 英文别名: 2-oxopentanedioic acid 1-(3-trifluoromethyl-benzyl) ester；2-oxopentanedioicacid 1-(3-trifluoromethyl-benzyl) ester；2-Oxoglutaric acid 1-[3-(trifluoromethyl)benzyl] ester；4,5-dioxo-5-[[3-(trifluoromethyl)phenyl]methoxy]pentanoic acid
• 化学式: C₁₃H₁₁F₃O₅
• 分子量: 304.223
• InChiKey: BJPZWCBMZXDKLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3-三氟甲基苯甲醇 在 三乙基硅烷 、 N-溴代丁二酰亚胺(NBS) 、 正丁基锂 、 N,N'-二环己基碳二亚胺 、 三氟乙酸 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 4.5h， 生成 1-TFMB KG
  参考文献：
  名称：

  Modular Synthesis of Cell-Permeating 2-Ketoglutarate Esters

  摘要：

  Cell-permeating esters of 2-ketoglutarate (2-KG) have been synthesized through a convergent sequence from two modules in two and three steps, respectively. This route provides access to a full series of mono- and disubstituted 2-KG esters, enabling us to define the effect of regioisomeric masking on metabolite release and antihypoxic activity in cell-based assays. In addition to providing insight into the biological activity of cell permeable 2-KG esters, the straightforward and modular nature of this synthetic route may prove useful for the development of next-generation 2-KG analogues for diagnostic and therapeutic applications.

  DOI：

  10.1021/acs.orglett.5b00737

文献信息

• [EN] ALPHA-KETOGLUTARATES AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] ALPHA-KÉTOGLUTARATES ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：CANCER REC TECH LTD

  公开号：WO2006016143A1

  公开（公告）日：2006-02-16

  The present invention relates generally to the field of pharmaceuticals and medicine. More particularly, the present invention relates to certain compounds (e.g., α-ketoglutarate compounds; compounds that activate HIFα hydroxylase; compounds that increases the level of α ketoglutarate, etc.) and their use in medicine, for example, in the treatment of cancer (e.g., cancer in which the activity of one of the enzymes in the tricarboxylic acid (TCA) cycle is down regulated), in the treatment of angiogenesis (e.g., hypoxia-induced angiogenesis). One preferred class of compounds are α-ketoglutarate compounds having a hydrophobic moiety that is, or is part of, an ester group formed from one of the acid groups of α ketogluartic acid; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N oxides, chemically protected forms, and prodrugs thereof.

  本发明涉及制药和医学领域，更具体地涉及某些化合物（例如α-酮戊二酸化合物；激活HIFα羟化酶的化合物；增加α-酮戊二酸水平的化合物等）及其在医学中的应用，例如用于癌症治疗（例如TCA循环中的一种酶活性下调的癌症），用于血管生成（例如缺氧诱导的血管生成）。其中一种优选的化合物类别是具有亲水性基团的α-酮戊二酸化合物，该亲水性基团是α-酮戊二酸中的酸基之一形成的酯基，以及其药用可接受的盐、溶剂化合物、酰胺、酯、醚、N-氧化物、化学保护形式和前药。
• METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS
  申请人：Dang Leonard Luan C

  公开号：US20150240286A1

  公开（公告）日：2015-08-27

  Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

  治疗和评估具有IDH新活性突变体（例如IDH1或IDH2）的受试者的方法。
• Alpha-Ketoglutarates and Their Use as Therapeutic Agents
  申请人：Gottlieb Eyal

  公开号：US20090005437A1

  公开（公告）日：2009-01-01

  The present invention relates generally to the field of pharmaceuticals and medicine. More particularly, the present invention relates to certain compounds (e.g., α-ketoglutarate compounds; compounds that activate HIFα hydroxylase; compounds that increases the level of α-ketoglutarate, etc.) and their use in medicine, for example, in the treatment of cancer (e.g., cancer in which the activity of one of the enzymes in the tricarboxylic acid (TCA) cycle is down regulated), in the treatment of angiogenesis (e.g., hypoxia-induced angiogenesis). One preferred class of compounds are α-ketoglutarate compounds having a hydrophobic moiety that is, or is part of, an ester group formed from one of the acid groups of α-ketogluartic acid; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof.

  本发明一般涉及制药和医学领域。更具体地说，本发明涉及某些化合物（例如α-酮戊二酸化合物；激活HIFα羟化酶的化合物；增加α-酮戊二酸水平的化合物等）及其在医学上的应用，例如治疗癌症（例如三羧酸循环中的酶活性被下调的癌症），治疗血管生成（例如缺氧诱导的血管生成）。一种首选的化合物类别是具有亲水性基团的α-酮戊二酸化合物，该亲水性基团是α-酮戊二酸的酸基之一形成的酯基或其一部分；以及其药学上可接受的盐、溶剂化物、酰胺、酯、醚、N-氧化物、化学保护形式和其前药。
• Methods for diagnosing IDH-mutant cell proliferation disorders
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US10711314B2

  公开（公告）日：2020-07-14

  Methods of diagnosing subjects having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with mutant IDH enzymes with 2HG neoactivity.

  诊断患有细胞增殖相关疾病或疑似患有细胞增殖相关疾病的受试者与具有 2HG 新生活性的突变 IDH 酶有关的方法。
• ALPHA-KETOGLUTARATES AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Cancer Research Technology Limited

  公开号：EP1778616A1

  公开（公告）日：2007-05-02